The family of Insulin like Growth Factor Binding Proteins (IGFBPs) share 50% amino acid identity with conserved N terminal and C terminal regions responsible for binding Insulin like Growth Factors I and II (IGF I and IGF II). Most circulating IGFs are in complexes with IGFBPs, which are believed to increase the residence of IGFs in the body, modulate availability of IGFs to target receptors for IGFs, reduce insulin like effects of IGFs, and act as signaling molecules independently of IGFs.
About 75% of circulating IGFs are in 1500 220 KDa complexes with IGFBP3 and ALS. Such complexes are too large to pass the endothelial barrier. The remaining 20 25% of IGFs are bound to other IGFBPs in 40 50 KDa complexes. IGFs are released from IGF:IGFBP complexes by proteolysis of the IGFBP. IGFs become active after release, however IGFs may also have activity when still bound to some IGFBPs.
IGFBP1 is enriched in amniotic fluid and is produced in the liver under control of insulin (insulin suppresses production). IGFBP1 binding stimulates IGF function. It is unknown which if any protease degrades IGFBP1.
IGFBP2 is enriched in cerebrospinal fluid; its binding inhibits IGF function. IGFBP2 is not significantly degraded in circulation.
IGFB3, which binds most IGF in the body is enriched in follicular fluid and found in many other tissues. IGFBP 3 may be cleaved by plasmin, thrombin, Prostate specific Antigen (PSA, KLK3), Matrix Metalloprotease-1 (MMP1), and Matrix Metalloprotease-2 (MMP2). IGFBP3 also binds extracellular matrix and binding lowers its affinity for IGFs. IGFBP3 binding stimulates the effects of IGFs.
IGFBP4 acts to inhibit IGF function and is cleaved by Pregnancy associated Plasma Protein A (PAPPA) to release IGF.
IGFBP5 is enriched in bone matrix; its binding stimulates IGF function. IGFBP5 is cleaved by Pregnancy Associated Plasma Protein A2 (PAPPA2), ADAM9, complement C1s from smooth muscle, and thrombin. Only the cleavage site for PAPPA2 is known.
IGFBP6 is enriched in cerebrospinal fluid. It is unknown which if any protease degrades IGFBP6.
Collett-Solberg PF, Nunn SE, Gibson TB, Cohen P.; ''Identification of novel high molecular weight insulin-like growth factor-binding protein-3 association proteins in human serum.''; PubMedEurope PMCScholia
Bach LA, Hsieh S, Brown AL, Rechler MM.; ''Recombinant human insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts.''; PubMedEurope PMCScholia
Galanis M, Firth SM, Bond J, Nathanielsz A, Kortt AA, Hudson PJ, Baxter RC.; ''Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3.''; PubMedEurope PMCScholia
Payet LD, Firth SM, Baxter RC.; ''The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers.''; PubMedEurope PMCScholia
Kuang Z, Yao S, McNeil KA, Thompson JA, Bach LA, Forbes BE, Wallace JC, Norton RS.; ''Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding.''; PubMedEurope PMCScholia
Headey SJ, Keizer DW, Yao S, Brasier G, Kantharidis P, Bach LA, Norton RS.; ''C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II.''; PubMedEurope PMCScholia
Butkowski RJ, Elion J, Downing MR, Mann KG.; ''Primary structure of human prethrombin 2 and alpha-thrombin.''; PubMedEurope PMCScholia
Byun D, Mohan S, Yoo M, Sexton C, Baylink DJ, Qin X.; ''Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.''; PubMedEurope PMCScholia
Booth BA, Boes M, Dake BL, Knudtson KL, Bar RS.; ''IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis.''; PubMedEurope PMCScholia
Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA.; ''The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.''; PubMedEurope PMCScholia
Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E.; ''IGF-binding protein-4: biochemical characteristics and functional consequences.''; PubMedEurope PMCScholia
Headey SJ, Leeding KS, Norton RS, Bach LA.; ''Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding.''; PubMedEurope PMCScholia
Belgorosky A, Rivarola MA.; ''Insulin-like growth factor binding protein (IGFBP)-3-bound IGF-I and IGFBP-3-bound IGF-II in growth hormone deficiency.''; PubMedEurope PMCScholia
Bond JJ, Meka S, Baxter RC.; ''Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6.''; PubMedEurope PMCScholia
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE.; ''Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.''; PubMedEurope PMCScholia
Janosi JB, Firth SM, Bond JJ, Baxter RC, Delhanty PJ.; ''N-Linked glycosylation and sialylation of the acid-labile subunit. Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs.''; PubMedEurope PMCScholia
Arai T, Parker A, Busby W, Clemmons DR.; ''Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes.''; PubMedEurope PMCScholia
Firth SM, Baxter RC.; ''Cellular actions of the insulin-like growth factor binding proteins.''; PubMedEurope PMCScholia
Qin X, Byun D, Lau KH, Baylink DJ, Mohan S.; ''Evidence that the interaction between insulin-like growth factor (IGF)-II and IGF binding protein (IGFBP)-4 is essential for the action of the IGF-II-dependent IGFBP-4 protease.''; PubMedEurope PMCScholia
Laursen LS, Overgaard MT, Nielsen CG, Boldt HB, Hopmann KH, Conover CA, Sottrup-Jensen L, Giudice LC, Oxvig C.; ''Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis.''; PubMedEurope PMCScholia
Twigg SM, Baxter RC.; ''Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit.''; PubMedEurope PMCScholia
Cianfarani S, Frost VJ, Savage MO, Holly JM.; ''Glucose does not influence the insulin-like growth factor (JGF) binding to carrier proteins (IGFBPs): analysis of rat and human serum by western ligand blotting.''; PubMedEurope PMCScholia
Lalou C, Silve C, Rosato R, Segovia B, Binoux M.; ''Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells.''; PubMedEurope PMCScholia
Binkert C, Landwehr J, Mary JL, Schwander J, Heinrich G.; ''Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2).''; PubMedEurope PMCScholia
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E.; ''Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?''; PubMedEurope PMCScholia
Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM.; ''Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6.''; PubMedEurope PMCScholia
Angelloz-Nicoud P, Harel L, Binoux M.; ''Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases.''; PubMedEurope PMCScholia
Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG.; ''Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.''; PubMedEurope PMCScholia
Holly J, Perks C.; ''The role of insulin-like growth factor binding proteins.''; PubMedEurope PMCScholia
Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P.; ''Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle.''; PubMedEurope PMCScholia
Baxter RC, Martin JL.; ''Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling.''; PubMedEurope PMCScholia
Choi KY, Kyung YJ, Lee CY, Lee DH.; ''Characterization of insulin-like growth factor-free interaction between insulin-like growth factor binding protein 3 and acid labile subunit expressed from Xenopus oocytes.''; PubMedEurope PMCScholia
Twigg SM, Kiefer MC, Zapf J, Baxter RC.; ''Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain.''; PubMedEurope PMCScholia
Yan X, Forbes BE, McNeil KA, Baxter RC, Firth SM.; ''Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation.''; PubMedEurope PMCScholia
Laursen LS, Kjaer-Sorensen K, Andersen MH, Oxvig C.; ''Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and -5.''; PubMedEurope PMCScholia
Bach LA, Rechler MM.; ''Measurement of insulin-like growth factor (IGF)-II binding to purified IGF binding proteins 1-6: comparison of charcoal adsorption and high performance size exclusion chromatography.''; PubMedEurope PMCScholia
Twigg SM, Kiefer MC, Zapf J, Baxter RC.; ''A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit.''; PubMedEurope PMCScholia
Gibson TL, Cohen P.; ''Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases.''; PubMedEurope PMCScholia
Angelloz-Nicoud P, Lalou C, Binoux M.; ''Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160) and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-like growth factor binding protein-3.''; PubMedEurope PMCScholia
Lalou C, Lassarre C, Binoux M.; ''Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3.''; PubMedEurope PMCScholia
Tagliabracci VS, Wiley SE, Guo X, Kinch LN, Durrant E, Wen J, Xiao J, Cui J, Nguyen KB, Engel JL, Coon JJ, Grishin N, Pinna LA, Pagliarini DJ, Dixon JE.; ''A Single Kinase Generates the Majority of the Secreted Phosphoproteome.''; PubMedEurope PMCScholia
Schneider MR, Zhou R, Hoeflich A, Krebs O, Schmidt J, Mohan S, Wolf E, Lahm H.; ''Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells.''; PubMedEurope PMCScholia
Campbell EJ, Silverman EK, Campbell MA.; ''Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity.''; PubMedEurope PMCScholia
Firth SM, Clemmons DR, Baxter RC.; ''Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding.''; PubMedEurope PMCScholia
Mohan S, Baylink DJ.; ''IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.''; PubMedEurope PMCScholia
Baxter RC, Bayne ML, Cascieri MA.; ''Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3.''; PubMedEurope PMCScholia
Angelloz-Nicoud P, Binoux M.; ''Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).''; PubMedEurope PMCScholia
Marinaro JA, Neumann GM, Russo VC, Leeding KS, Bach LA.; ''O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis.''; PubMedEurope PMCScholia
Okabe E, Kajihara J, Usami Y, Hirano K.; ''The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3.''; PubMedEurope PMCScholia
Wolf E, Lahm H, Wu M, Wanke R, Hoeflich A.; ''Effects of IGFBP-2 overexpression in vitro and in vivo.''; PubMedEurope PMCScholia
Andrade D, Assis DM, Santos JA, Alves FM, Hirata IY, Araujo MS, Blaber SI, Blaber M, Juliano MA, Juliano L.; ''Substrate specificity of kallikrein-related peptidase 13 activated by salts or glycosaminoglycans and a search for natural substrate candidates.''; PubMedEurope PMCScholia
Baxter RC, Meka S, Firth SM.; ''Molecular distribution of IGF binding protein-5 in human serum.''; PubMedEurope PMCScholia
Cohen P, Peehl DM, Graves HC, Rosenfeld RG.; ''Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.''; PubMedEurope PMCScholia
Payet LD, Wang XH, Baxter RC, Firth SM.; ''Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions.''; PubMedEurope PMCScholia
Gyrup C, Oxvig C.; ''Quantitative analysis of insulin-like growth factor-modulated proteolysis of insulin-like growth factor binding protein-4 and -5 by pregnancy-associated plasma protein-A.''; PubMedEurope PMCScholia
Laursen LS, Overgaard MT, Søe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C.; ''Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A.''; PubMedEurope PMCScholia
Siwanowicz I, Popowicz GM, Wisniewska M, Huber R, Kuenkele KP, Lang K, Engh RA, Holak TA.; ''Structural basis for the regulation of insulin-like growth factors by IGF binding proteins.''; PubMedEurope PMCScholia
Lee KO, Oh Y, Giudice LC, Cohen P, Peehl DM, Rosenfeld RG.; ''Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients.''; PubMedEurope PMCScholia
Fielder PJ, Rosenfeld RG, Graves HC, Grandbois K, Maack CA, Sawamura S, Ogawa Y, Sommer A, Cohen P.; ''Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3.''; PubMedEurope PMCScholia
This CandidateSet contains sequences identified by William Pearson's analysis of Reactome catalyst entities. Catalyst entity sequences were used to identify analagous sequences that shared overall homology and active site homology. Sequences in this Candidate set were identified in an April 24, 2012 analysis.
This CandidateSet contains sequences identified by William Pearson's analysis of Reactome catalyst entities. Catalyst entity sequences were used to identify analagous sequences that shared overall homology and active site homology. Sequences in this Candidate set were identified in an April 24, 2012 analysis.
Matrix Metalloprotease-1 and -2 cleave IGFBP-3 in the IGF:IGFBP-3:ALS Complex between amino acids 126 and 127, releasing IGF. The reaction has been demonstrated in vivo.
Prostate specific Antigen (PSA, KLK3) cleaves IGFBP-3 in the IGF:IGFBP-3:ALS Complex between amino acids 186 and 187. Other cleavage sites were observed but not reproducibly. These may have been caused by impurities in the PSA preparation.
IGFBP 1 binds IGF I or IGF II via the conserved N terminus and C terminus of IGFBP 1.
IGFBP 1 is enriched in amniotic fluid and is produced in the liver under control of insulin (insulin suppresses production). IGFBP 1 acts to stimulate IGF function. It is unknown which if any protease degrades IGFBP 1.
IGFBP3 binds IGF I or IGF II via the conserved N terminus and C terminus of IGFBP 3. IGFBP3 also binds ALS via the C terminal portion of IGFBP3. The interaction is dependent on the glycosylation of ALS. IGFBP3, which binds most IGF in the body, is enriched in follicular fluid and found in many other tissues. IGFBP3 may be cleaved by plasmin, thrombin, Prostate specific Antigen (PSA, KLK3), Matrix Metalloprotease-1 (MMP1), and Matrix Metalloprotease-2 (MMP2). IGFBP3 also binds extracellular matrix and binding lowers its affinity for IGFs. IGFBP3 stimulates the effects of IGFs.
Both Pregnancy Associated Plasma Protein A (PAPP-A) and A2 (PAPP-A2) cleave IGFBP-5 in the IGF:IGFBP-5:ALS Complex between amino acids 163 and 164, releasing IGF. PPAP-A has also been shown to cleave IGFBP-5 that is not complexed with IGF.
IGFBP 5 binds IGF I or IGF II via the conserved N terminus and C terminus of IGFBP 5. IGFBP 5 also binds ALS via the central portion of IGFBP 5. About 55% of IGF:IGFBP 5 complexes contain ALS.
IGFBP 5 is enriched in bone matrix and acts to stimulate IGF function. IGFBP 5 is cleaved by Pregnancy associated Plasma Protein A2 (PAPP A2), ADAM 9, complement C1s from smooth muscle, and thrombin. Only the cleavage site for PAPP A2 is known.
About 55% of IGF:IGFBP 5 complexes contain ALS; 45% contain only IGF and IGFBP 5.
Extracellular serine/threonine protein kinase FAM20C is an extracellular kinase that can phosphorylate a broad range of secreted protein. FAM20C is bound and allosterically activated by the pseudokinase FAM20A (Tagliabracchi et al. 2012, 2015, Cui et al. 2015). Loss of function mutations in Fam20C cause Raine Syndrome, an osteosclerotic bone dysplasia (Faundes et al. 2014).
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
Annotated Interactions
IGFBP 2 is enriched in cerebrospinal fluid and inhibits IGF function. IGFBP 2 is not significantly degraded in circulation.
IGFBP 1 is enriched in amniotic fluid and is produced in the liver under control of insulin (insulin suppresses production). IGFBP 1 acts to stimulate IGF function. It is unknown which if any protease degrades IGFBP 1.
IGFBP3, which binds most IGF in the body, is enriched in follicular fluid and found in many other tissues. IGFBP3 may be cleaved by plasmin, thrombin, Prostate specific Antigen (PSA, KLK3), Matrix Metalloprotease-1 (MMP1), and Matrix Metalloprotease-2 (MMP2). IGFBP3 also binds extracellular matrix and binding lowers its affinity for IGFs. IGFBP3 stimulates the effects of IGFs.
IGFBP 5 is enriched in bone matrix and acts to stimulate IGF function. IGFBP 5 is cleaved by Pregnancy associated Plasma Protein A2 (PAPP A2), ADAM 9, complement C1s from smooth muscle, and thrombin. Only the cleavage site for PAPP A2 is known. About 55% of IGF:IGFBP 5 complexes contain ALS; 45% contain only IGF and IGFBP 5.
Loss of function mutations in Fam20C cause Raine Syndrome, an osteosclerotic bone dysplasia (Faundes et al. 2014).